The company is collaborating with two UK institutes to assess whether its Signatera ctDNA technology can detect disease recurrence in women treated for breast cancer.
Areas of concern are the recruitment of talented scientists, as well as retaining access to EU funding, European research collaborations, and clinical trials.
A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.
The two studies came out of the UK's Tracking Cancer Evolution through Therapy (TRACERx) trial.
Speakers at the conference's opening plenary showed how their work in cancer research fit into the broad theme of 'Discover, Predict, Prevent, Treat.'
The new funding supports clinical trials as well as preclinical work to identify biomarkers of therapeutic response.
The researchers will sequence the genomes and transcriptomes of 250 breast cancer patients in the first phase, returning information from 16 actionable genes.
Inivata plans to use the new funds to accelerate clinical studies to validate its liquid biopsy technology platform and commercialize its first products.
The work identified specific groups of somatic mutations that might be ideal to hunt for in ctDNA to monitor tumor burden, guide treatment, or follow therapeutic response.
The institute will house more than 1,200 scientists researching cancer, heart disease, lung disease, infectious disease, and other ailments.
A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.
Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.
In Science this week: CRISPR-based approach for recording cellular events, and more.
A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.